



ORIGINAL ARTICLE

Is the PARADIGM-HF cohort representative of the real-world heart failure patient population?



Gustavo Rodrigues*, António Tralhão, Carlos Aguiar,
Pedro Freitas, António Ventosa, Miguel Mendes

Hospital de Santa Cruz, CHLO, Lisbon, Portugal

Received 13 March 2017; accepted 29 September 2017
Available online 17 May 2018

KEYWORDS

Heart failure;
Sacubitril/valsartan;
Reduced ejection
fraction;
Medical therapy

Abstract

Introduction: A new drug with prognostic impact on heart failure, sacubitril/valsartan, has been introduced in current guidelines. However, randomized trial results can be compromised by lack of representativeness. We aimed to assess the representativeness of the PARADIGM-HF trial in a real-world population of patients with heart failure.

Methods: We reviewed the records of 196 outpatients followed in a heart failure clinic between January 2013 and December 2014. After exclusion of 44 patients with preserved ejection fraction, the inclusion and exclusion criteria of the trial were applied.

Results: Of the 152 patients with systolic heart failure, 106 lacked one or more inclusion criteria and 45 had at least one exclusion criterion. Considering only patients with ejection fraction $\leq 35\%$ (HFrEF) (n=88), 43 patients lacked at least one inclusion criterion and 25 patients had at least one exclusion criterion. Combining the inclusion and exclusion criteria, 24.3% of patients with systolic HF (ejection fraction $\leq 50\%$) and 42% of patients with HFrEF would be eligible for the PARADIGM-HF trial.

Conclusion: One in four patients with systolic HF followed in a heart failure outpatient clinic would fulfill the reference study criteria for treatment with the new drug, sacubitril/valsartan.

© 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: gustavo_rodrigues17@hotmail.com (G. Rodrigues).

PALAVRAS-CHAVE

Insuficiência cardíaca;
Sacubitril-valsartan;
Fração de ejeção reduzida;
Terapêutica médica

Será a coorte do PARADIGM-HF representativa da população do mundo real de doentes com insuficiência cardíaca?**Resumo**

Introdução: Um novo medicamento com impacto prognóstico em doentes com insuficiência cardíaca foi introduzido nas *guidelines* mais recentes. Contudo, os resultados de estudos aleatorizados podem ser prejudicados pela falta de representatividade. Os autores ambicionam avaliar a representatividade do estudo PARADIGM-HF numa população do mundo real de doentes com insuficiência cardíaca.

Métodos: Foram revistos os registos de 196 pacientes seguidos em consulta dedicada a insuficiência cardíaca de um hospital terciário entre janeiro de 2016 e dezembro de 2014. Após exclusão de 44 doentes com fração de ejeção preservada, os critérios de inclusão e exclusão foram aplicados.

Resultados: Dos 152 doentes com insuficiência cardíaca com disfunção sistólica, 106 não preenchiam um ou mais critérios de inclusão e tinham pelo menos um critério de exclusão. Considerando apenas os doentes com fração de ejeção $\leq 35\%$ (N = 88), 43 doentes não preenchiam pelo menos um critério de inclusão e 25 tinham pelo menos um critério de exclusão. Combinando os critérios de inclusão e exclusão, 24,3% dos doentes com fração de ejeção $< 50\%$ e 42% dos doentes com fração de ejeção ventricular esquerda reduzida seriam elegíveis para o estudo PARADIGM-HF.

Conclusão: Um em cada quatro doentes com insuficiência cardíaca sistólica, seguidos em ambulatório na consulta de insuficiência cardíaca, cumpririam os critérios do estudo de referência que levou à aprovação do novo fármaco inibidor dos recetores de angiotensina e da neprilisina. © 2018 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

Introduction

The mainstay of the management of chronic systolic heart failure (HF) is neurohormonal blockade specifically targeting the sympathetic nervous system and the renin-angiotensin-aldosterone system.¹⁻³ Yet, despite the use of beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and aldosterone receptor antagonists in optimized doses, mortality and morbidity remain high in these patients.¹

Several randomized controlled trials over a period of more than a decade exploring other potential therapeutic targets, such as endothelin, vasopressin and tumor necrosis factor alpha, failed to demonstrate further reductions in mortality.⁴⁻⁷ This period of consecutive negative study outcomes ended in 2014, when the PARADIGM-HF trial results were reported. In PARADIGM-HF the combination of a neprilysin inhibitor (sacubitril) and an ARB (valsartan) was superior to enalapril in reducing the risk of death from cardiovascular causes and hospitalization for heart failure in patients with chronic systolic HF on optimized medical therapy.⁸

After its efficacy is proven, a new drug has to show effectiveness under real-life conditions.^{9,10} In a real-world setting, the representativeness of randomized clinical trials findings may be limited, since these studies are conducted under idealized and rigorously controlled conditions that may compromise their external validity. Ineligibility rates in cardiology trials show that as many as 25-67% of the general disease population are excluded from these trials.^{11,12}

Therefore, we aimed to assess the representativeness of PARADIGM-HF in a real-world population of patients with systolic HF.

Methods**Population and design**

The records of all outpatients (n=196) followed in the heart failure clinic of a tertiary university-affiliated hospital between January 2013 and December 2014 were reviewed. Standard of care includes a regular clinical assessment every 3-6 months, drug titration, follow-up inquiry and serial N-terminal pro-brain natriuretic peptide (NT-proBNP) measurement. All data are included in a prospective registry. Patients with preserved left ventricular ejection fraction (LVEF), defined as LVEF $\geq 50\%$, were excluded (n=44). The inclusion and exclusion criteria of the PARADIGM-HF trial were subsequently applied to the remaining population.

Patients were considered eligible for treatment with sacubitril/valsartan if they fulfilled all of the following criteria: New York Heart Association (NYHA) functional class II-IV; LVEF $\leq 35\%$; NT-proBNP ≥ 600 pg/ml. Furthermore, eligible patients had to be taking enalapril 10 mg twice daily (used as an entry criterion in PARADIGM-HF) or equivalent (defined by target dosage in the current guidelines) as part of their optimal medical therapy.¹ All LVEF measurements were obtained by two-dimensional transthoracic echocardiography. Patients were considered ineligible for treatment

with sacubitril/valsartan if they presented any of the conditions listed in [Table 1](#).

Statistical analysis

Continuous variables with a normal distribution are expressed as means \pm standard deviation. Discrete variables are expressed as frequencies and percentages. When appropriate, 95% confidence intervals (CI) or percentiles were calculated. The statistical analysis was performed using SPSS software, version 21.0 (IBM SPSS Inc., Chicago, IL, USA).

Results

Of the 196 HF patients initially screened, 44 were excluded due to preserved LVEF. Of the remaining 152 patients with LVEF $<50\%$ (systolic HF), 75% were male, mean age was 66 ± 12.8 years, and mean LVEF was $34.9 \pm 9.0\%$. Other baseline characteristics are displayed in [Table 2](#).

Of the 152 patients with systolic HF 106 (69.7%) failed to meet at least one inclusion criterion and 45 (29.6%) had at least one exclusion criterion. Considering only patients with HFrEF (LVEF $\leq 35\%$) ($n=88$), 43 (48.9%) lacked at least one inclusion criterion and 25 (28.4%) had at least one exclusion criterion. Combining inclusion and exclusion criteria, 24.3% ($n=37$) of patients with systolic HF and 42% ($n=37$) of patients with HFrEF would have been eligible for the PARADIGM-HF trial ([Table 3](#)).

The inclusion criterion most often missing in the population with systolic HF was LVEF $\leq 35\%$ (41.4%), followed by ACEI/ARB dose equal or equivalent to 20 mg enalapril daily (30.9%). The most frequent exclusion criteria in this group were hypotension (8.2%) and estimated life expectancy <5 years (7.9%). Considering only patients with HFrEF, the most frequent missing inclusion criteria were ACEI/ARB dose equal or equivalent to 20 mg enalapril daily (28.4%) and NT-proBNP ≥ 600 pg/ml (20.4%). The exclusion criteria more often present were hypotension (10.2%) and estimated glomerular filtration rate <30 ml/min/1.73 m² (10.2%). The distribution of patients according to the number of unfulfilled eligibility criteria and number of ineligibility criteria present is shown in [Figure 1](#).

Discussion

Our analysis shows that, if the PARADIGM-HF study criteria were applied to a real-world population of HF patients, only two in five patients with systolic HF would be deemed eligible for treatment with the novel angiotensin receptor-neprilysin inhibitor.

As pointed out by Wieringa et al.,¹³ Maggioni et al.¹⁴ and Niederseer et al.,¹⁵ real-world heart failure patients are different from the populations of randomized trials. Our population differs from PARADIGM-HF patients in several aspects: LVEF $\leq 35\%$ and ACEI/ARB dosage of at least enalapril 20 mg daily or equivalent (the minimum required dosage) were the most frequently unmet eligibility criteria, while symptomatic hypotension and severe chronic kidney disease were the most prevalent ineligibility criteria ([Table 3](#)).

Patient selection for randomized trials may influence the effectiveness and safety of a new drug in the real world, due to different comorbid conditions, differing age groups, race, gender and ethnic variances, and different concomitant drugs, disease severity and compliance.^{11,12,16} Heart failure patients are often very complex, increasingly with multiple comorbidities, partly due to prolonged life expectancy. This heterogeneity has the potential to preclude a wider generalization of trial results (obtained using a strict protocol) to the unselected population encountered in daily clinical practice.^{11,13–15}

The higher incidences of hypotension and severe chronic disease suggest that, as expected in tertiary reference centers, a sicker group of patients are being managed, who may be more susceptible to drugs with blood pressure-lowering effects. These features possibly contributed to the difficulty of ACEI or ARB titration up to the dose of 20 mg enalapril equivalent daily required in PARADIGM-HF.

The requirement for severely compromised LVEF, baseline NT-proBNP ≥ 600 pg/ml (BNP ≥ 150 pg/ml) and persistent HF symptoms despite optimal medical therapy, as applied in PARADIGM-HF, identifies higher-risk patients, facilitating the demonstration of a positive effect on HF prognosis.

In PARADIGM-HF, a protocol amendment changed the initial maximum LVEF permitted by the study protocol from

Table 1 Criteria of ineligibility for treatment with sacubitril/valsartan.

Known history of angioedema	History of severe pulmonary disease
Symptomatic hypotension and/or systolic blood pressure ≤ 95 mmHg	Diagnosis of peripartum- or chemotherapy-induced cardiomyopathy
eGFR ≤ 30 ml/min/1.73 m ²	Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to LV dilatation
Serum potassium ≥ 5.4 mmol/l	Presence of other hemodynamically significant obstructive lesions of the LV outflow tract
Coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months	Contraindication to or any condition which might significantly alter the absorption, distribution, metabolism, or excretion of sacubitril/valsartan
History of heart transplantation or on a transplant list or with LV assist device	

eGFR: estimated glomerular filtration rate; LV: left ventricular.

Table 2 Baseline characteristics of the study population.

	HFrEF (n=88)	Systolic HF (n=152)	PARADIGM-HF (n=4187)
Male	73 (83%)	114 (75%)	3308 (79%)
Age, years	65.0±13.8	66.0±12.8	63.8±11.5
LVEF, %	28.0±5.2	34.9±9.0	29.6±6.1
Caucasian	85 (96.6%)	146 (96%)	2763 (66%)
Diabetes	33 (37.5%)	55 (36.2%)	1451 (34.7%)
Hypertension	51 (58%)	89 (58.5%)	2969 (70.9%)
Dyslipidemia	39 (44.3%)	69 (45.4%)	-
BMI, kg/m ²	27.0±5.6	27.3±5.4	28.1±5.5
eGFR <60 ml/min/1.73 m ²	43 (48.9%)	61 (40.1%)	-
CRT	29 (33%)	42 (27.6%)	292 (7%)
Pacemaker	4 (4.5%)	4 (2.6%)	-
Atrial fibrillation	25 (28.4%)	39 (25.6%)	1517 (36.2%)
ICD	36 (40.9%)	46 (30.3%)	623 (14.9%)
CAD history	54 (61.4%)	81 (53.3%)	1818 (43.4%)
SBP, mmHg	116±16.9	119.4±17.4	122±15
Heart rate, bpm	67.3±11.8	66.5±11.9	72±12
Creatinine, mg/dl	1.4±1.1	1.37±1.1	1.13±0.3
Urea, mg/dl	67.6±38.4	65.1±34.1	-
Potassium, mmol/l	4.4±0.44	4.7±0.45	-
Sodium, mmol/l	141±3.7	140±3.7	-
NT-proBNP, pg/ml	3731 [664-3790]	3426 [454-3115]	1631 [885-3154]
ACEI or ARB	88 (100%)	152 (100%)	4195 (100%)
Beta-blocker	88 (100%)	152 (100%)	3899 (93.1%)
MRA	16 (18.2%)	33 (21.7%)	2271 (54.2%)
Ivabradine	12 (13.6%)	5 (3.3%)	-
NYHA I	10 (11.4%)	30 (19.7%)	180 (4.3%)
NYHA II	65 (73.8%)	104 (68.4%)	2998 (71.6%)
NYHA III	13 (14.8%)	18 (11.8%)	969 (23.1%)

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor antagonist; BMI: body mass index; CAD: coronary artery disease; CRT: cardiac resynchronization therapy; eGFR: estimated glomerular filtration rate; HFrEF: heart failure with reduced ejection fraction (LVEF ≤35%); ICD: implantable cardioverter-defibrillator; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; NYHA: New York Heart Association class; SBP: systolic blood pressure; Systolic HF: heart failure with LVEF ≤50%.

40% to 35% in order to select higher-risk patients.^{8,17} However, the exclusion of patients with mild or moderate LV systolic dysfunction from the PARADIGM-HF trial does not necessarily mean that patients with LVEF between 35% and 50% will not derive benefit. As all patients with reduced LVEF share the same neurohormonal changes, the significant benefits observed in PARADIGM-HF can be expected to apply to all of them, although not necessarily to the same extent. Some previous heart failure trials that led to the approval of various drugs with survival advantage suggested that the benefit was less in patients with higher LVEF, while others found no difference.¹⁸⁻²² A recent analysis by Solomon et al. demonstrated that LVEF does not influence the impact of sacubitril/valsartan on outcomes.²³ An ongoing study (PARAGON-HF) is assessing the combination of sacubitril and valsartan in HF patients with LVEF ≥45%.

Optimal medical management has been shown to reduce natriuretic peptide levels and to render HF patients asymptomatic, despite underlying severe LV systolic dysfunction.²⁴⁻²⁷ Although not represented in PARADIGM-HF, it is not unreasonable to anticipate a positive effect of the sacubitril/valsartan combination in delaying disease progression in asymptomatic patients.²⁸

Another pertinent feature in all trials is safety. Many exclusion criteria such as hypotension, hyperkalemia or severe chronic kidney disease relate to common concerns in the daily management of HF patients. Sicker patients have a higher incidence of adverse effects and are frequently excluded from HF trials like PARADIGM-HF, limiting the applicability of a new drug for many patients and reflecting the challenging nature of HF outpatient management.^{14,15}

The exclusion of patients who cannot tolerate enalapril 20 mg daily could restrict the use of the new drug in such patients, due to a possible greater risk of a collateral event, requiring closer monitoring in this subgroup. Our population was older, had worse renal function, higher NT-proBNP levels and more implantable devices, possibly representing a sicker group of patients, which would have contributed to the exclusion of some.

Once efficacy has been proved, novel treatments should be assessed for their effectiveness.²⁹ Our study provides an indication of which patient characteristics may influence the effectiveness of sacubitril/valsartan in a real-world population.

This study presents certain limitations, some of them inherent to a single-center registry. Also, optimal follow-up in the HF clinic could have contributed to the higher

Table 3 PARADIGM-HF inclusion and exclusion criteria in the study population.

	Systolic HF (n=152)	HFrEF (n=88)
<i>Inclusion criteria missing</i>		
NYHA >1	30 (19.7%)	10 (11.3%)
LVEF ≤35%	63 (41.4%)	0 (0%)
NT-proBNP ≥600 pg/ml	42 (27.6%)	18 (20.4%)
ACEI/ARB equal or equivalent to enalapril 20 mg daily	47 (30.9%)	25 (28.4%)
Beta-blocker	4 (2.6%)	1 (1.1%)
<i>Exclusion criteria present</i>		
Symptomatic hypotension	15 (8.2%)	9 (10.2%)
SBP <95 mmHg	6 (3.9%)	6 (6.8%)
eGFR <30 ml/min/1.73 m ²	11 (7.2%)	9 (10.2%)
Potassium >5.4 mmol/l	7 (4.6%)	4 (4.5%)
Previous angioedema	1 (0.7%)	0 (0%)
Transplant list	2 (1.3%)	2 (2.3%)
Severe pulmonary disease	3 (2%)	1 (1.1%)
Peripartum- or CT-induced HF	2 (1.3%)	0 (0%)
Severe valvular disease	3 (1.3%)	1 (1.1%)
Severe gastrointestinal or liver disease	4 (1.3%)	2 (1.1%)
Life expectancy <5 years	12 (7.9%)	8 (9.1%)

ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CT: chemotherapy; eGFR: estimated glomerular filtration rate; HF: heart failure; HFrEF: heart failure with reduced ejection fraction (LVEF ≤35%); LVEF: left ventricular ejection fraction; NYHA: New York Heart Association class; SBP: systolic blood pressure; Systolic HF: heart failure with LVEF ≤50%.




Figure 1 Distribution of patients according to number of unfulfilled eligibility criteria (A) and number of ineligibility criteria present (B) for treatment with sacubitril/valsartan according to PARADIGM-HF.

proportion of NYHA class I patients. Lastly, we cannot be sure whether a number, albeit probably small, of patients with HF symptoms were followed in general cardiology consultations and were thus not included in this analysis.

Conclusion

Despite the strictness of our standard protocol, about two in five of our real-world patients with systolic HF would be considered eligible for PARADIGM-HF, a significant number. This finding puts into perspective the applicability of PARADIGM-HF to the real-world population of HF patients. A larger registry with outcome analysis is needed to validate a wider use of the new drug.

Conflicts of interest

The authors have no conflicts of interest to declare.

The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. This study was investigator-driven and independent of any commercial funding.

References

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*. 2016;37:2129–200.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical

- Practice Guidelines and the Heart Failure Society of America. *Journal of Cardiac Failure*. 2016.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2013;62:e147–239.
 4. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *Jama*. 2007;297:1319–31.
 5. Ambrosy A, Goldsmith SR, Gheorghiade M. Tolvaptan for the treatment of heart failure: a review of the literature. *Expert Opinion on Pharmacotherapy*. 2011;12:961–76.
 6. Sinagra E, Perricone G, Romano C, et al. Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. *European Journal of Internal Medicine*. 2013;24:385–92.
 7. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension—a multi-center randomized study. *Cardiology*. 2008;109:273–80.
 8. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *The New England Journal of Medicine*. 2014;371:993–1004.
 9. Black N. Why we need observational studies to evaluate the effectiveness of health care. *BMJ*. 1996;312:1215–8.
 10. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. *The New England Journal of Medicine*. 1993;329:2029–32.
 11. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. *Trials*. 2015;16:495.
 12. Wang TS, Hellkamp AS, Patel CB, et al. Representativeness of RELAX-AHF clinical trial population in acute heart failure. *Circulation Cardiovascular Quality and Outcomes*. 2014;7:259–68.
 13. Wieringa NF, Vos R, van der Werf GT, et al. Co-morbidity of 'clinical trial' versus 'real-world' patients using cardiovascular drugs. *Pharmacoepidemiology and Drug Safety*. 2000;9:569–79.
 14. Maggioni AP, Orso F, Calabria S, et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. *European Journal of Heart Failure*. 2016;18:402–10.
 15. Niederseer D, Thaler CW, Niederseer M, et al. Mismatch between heart failure patients in clinical trials and the real world. *International Journal of Cardiology*. 2013;168:1859–65.
 16. Udell JA, Wang TY, Li S, et al. Clinical trial participation after myocardial infarction in a national cardiovascular data registry. *Jama*. 2014;312:841–3.
 17. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). *European Journal of Heart Failure*. 2013;15:1062–73.
 18. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *The New England journal of medicine* 1991;325:293–302.
 19. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *European Heart Journal*. 2005;26:215–25.
 20. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. *The New England journal of medicine* 1992;327:685–91.
 21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *The New England Journal of Medicine*. 1999;341:709–17.
 22. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. *The New England Journal of Medicine*. 2001;344:1651–8.
 23. Solomon SD, Claggett B, Desai AS, et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. *Circulation Heart Failure*. 2016;9:e002744.
 24. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). *Circulation*. 2002;106:2454–8.
 25. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. *Journal of the American College of Cardiology*. 2001;37:1228–33.
 26. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. *Journal of the American College of Cardiology*. 1998;32:1811–8.
 27. Li N, Wang JA. Brain natriuretic peptide and optimal management of heart failure. *Journal of Zhejiang University Science B*. 2005;6:877–84.
 28. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation*. 2015;131:54–61.
 29. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. *Circulation*. 2008;118:1294–303.